Trial results

Cognitive Dysfunction and Glucagon-like Peptide-1 Agonists

NCT02423824 on ClinicalTrials.gov · last registry update 2016-05-13

A small phase 3 — 21 participants, against a typical 424. The sponsor logged completion for April 2016. Primary outcome, as filed: Executive function. liraglutide is approved in the US, but not for psychiatric — a registration here is not an approval, and most drugs tested in a new condition never get one for it.

Status

COMPLETED

Phase

P3

Drug

liraglutide

Saxenda, Victoza, Xultophy

Sponsor

University Health Network, Toronto

Sponsor type

Other

Enrollment

21

Started

2015-05

Primary completion

2016-04 actual

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

Executive function

Conditions studied

Bipolar Disorder · Major Depressive Disorder

Every field above is taken directly from the registry record. See all detected changes across the class, or the liraglutide page for this molecule’s full trial and approval history.